June 16, 2026 Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer’s
June 9, 2026 AlzeCure Pharma enters into a collaboration and out-licensing agreement with Lilly for Alzheimer’s project
June 5, 2026 AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document
May 19, 2026 AlzeCure Pharma to host live seminar on the pain project TrkA-NAM ACD137 with a focus on osteoarthritis and neuropathic pain
April 24, 2026 AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million
April 20, 2026 Last patient has completed AlzeCure’s Phase Ib clinical study with NeuroRestore ACD856
March 19, 2026 AlzeCure presents new preclinical data with NeuroRestore ACD856 at the Alzheimer’s Conference AD/PD
February 3, 2026 AlzeCure abstract on NeuroRestore ACD856 accepted at the Alzheimer’s conference AP/PD 2026
